奧翔藥業(603229.SH):子公司阿茲夫定片相關生產線通過藥品GMP符合性檢查
格隆匯5月5日丨奧翔藥業(603229.SH)公佈,全資子公司浙江麒正藥業有限公司從浙江省藥品監督管理局網站獲悉藥品GMP符合性檢查結果公吿,主要生產品種阿茲夫定片,本次為麒正藥業相關生產線首次通過GMP符合性檢查,表明麒正藥業相關生產線符合GMP要求。
河南真實生物科技有限公司的阿茲夫定於2021年獲得國家藥監局批准用於HIV的治療。2022年7月25日,國家藥監局應急附條件批准阿茲夫定片用於治療新型冠狀病毒。公司未能從公開渠道獲得該產品的銷售數據。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.